Isotina

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Isotina

Property Description
Active Ingredient Isotretinoin (13-cis-retinoic acid)
Form Soft gelatin capsules
Pharmacological Class Retinoid (Systemic Dermatological Agent)
Route of Administration Oral
Origin Synthetic derivative of Vitamin A

The Core Identity and Classification of Isotina

Isotina is a powerful, prescription-only synthetic medicine whose sole active ingredient is Isotretinoin, also known chemically as 13-cis-retinoic acid. It is classified within the retinoid pharmacological class, defining it as a structural derivative of Vitamin A. Isotretinoin is an established drug for severe dermatological issues.

This agent is administered through the oral route, providing systemic action, and is physically presented as soft gelatin capsules. As a highly lipophilic substance, the active ingredient is suspended within the capsule shell in an oily vehicle, such as hydrogenated soybean oil, which is critical for ensuring adequate and consistent absorption into the body. This specific formulation is clinically recognized for providing the necessary bioavailability for systemic effects.


Isotina: Systemic Purpose and Fundamental Action

The general purpose of this systemic medication is to exert profound, long-term influence over fundamental processes within the skin. Its primary mechanism involves exerting a potent influence on the sebaceous glands, which are responsible for producing sebum (skin oil). Isotretinoin is a potent inhibitor of sebum production. This action is widely recognized in dermatological practice as a key step toward achieving remission in severe, nodular conditions.

Concurrently, Isotretinoin normalizes the faulty growth and shedding of skin cells, restoring proper cell differentiation and turnover within the skin structures. This robust, dual-action principle achieves systemic control by modifying the inherent physiology of the sebaceous unit. The objective is to fundamentally alter the underlying conditions, rather than simply treating surface symptoms, offering a deep and enduring effect.

Regulatory References

  1. Isotretinoin: MedlinePlus Drug Information

What side effects are possible with Isotina?

Possible side effects and safety information

The safety profile of Isotina (Isotretinoin) is comprehensively documented in regulatory labeling, reflecting its classification as a potent systemic retinoid. The official framework categorizes adverse events by frequency and the body system affected.

Frequency and System-Specific Reactions

The most common adverse reactions are generally classified as very common (ge 1/10) in regulatory documents and primarily involve the Skin and Subcutaneous Tissue Disorders system. These frequently include cheilitis (dry lips), dry skin (xerosis), and epistaxis (nosebleeds). The Musculoskeletal and Connective Tissue Disorders system is also commonly affected, with reported back pain and arthralgia (joint pain). Effects on the Eye Disorders system typically include dry eye and conjunctivitis.

Serious Adverse Reactions and Safety Constraints

The most critical constraint is the risk of Embryofetal Toxicity (teratogenicity), which makes the medicine strictly contraindicated during pregnancy due to the high risk of severe, documented birth defects. Serious adverse events documented across systems include Pseudotumor cerebri (increased brain pressure), severe psychiatric effects (including depression and suicidal ideation), and severe Gastrointestinal Disorders such as Inflammatory Bowel Disease (IBD) and acute pancreatitis. The label also notes that effects such as decreased night vision may persist in some individuals after treatment is stopped. The medicine is not recommended in individuals with severe hepatic impairment and is constrained by prohibitions on co-administration with tetracycline antibiotics.

Overdose and Emergency Response

The official regulatory documentation for Isotina (Isotretinoin) overdose focuses on two critical areas: the documented clinical manifestations and the required, life-saving emergency actions. Acute overdose in humans is associated with symptoms that are officially noted to be similar to those of acute hypervitaminosis A. These transient manifestations may involve the central nervous system, gastrointestinal tract, and skin, presenting as vomiting, headache, dizziness, ataxia (loss of coordinated movement), abdominal pain, facial flushing, and cheilosis (chapped lips). Regulatory information specifies that these acute symptoms are typically documented as resolving quickly without apparent residual effects.

Despite the often-transient nature of acute symptoms, the most significant risk associated with any overexposure is the life-threatening teratogenicity. For this reason, regulatory authorities mandate that immediate medical attention must be sought for any suspected overdose. A critical, specific regulatory action is required for patients who can become pregnant: they must be evaluated for pregnancy and receive counseling about the severe risks to the fetus. Management for the acute symptoms is symptomatic and supportive treatment, a necessity stated in regulatory documents because no specific antidote is known. This dual focus defines the entire official overdose profile and dictates the urgency for seeking help.

Therapeutic Uses of Isotina

What Isotina Treats: Main Uses and Benefits

Isotina is a systemic medicine primarily used to address severe recalcitrant nodular acne, a chronic skin condition that involves deep, painful cysts and nodules. The therapeutic focus of Isotina is intended for severe acne that may be resistant to other treatments.

It is commonly used across conditions presenting with periods of heightened symptoms, specifically for acne vulgaris that has demonstrated resistance to standard therapies like systemic antibiotics and topical regimens. This supportive treatment is relevant for easing deep inflammation and managing the symptoms related to excessive oil production, which are common symptomatic manifestations.

The medicine may be part of symptomatic management applied in scenarios where additional management of discomfort is required. The key indications involve managing severe acne, nodulocystic acne, and acne associated with a high risk of permanent scarring. A key patient-oriented benefit may be helping to achieve sustained acne clearance and prolonged remission after a treatment course is completed.

Quick Fact: Relief for Deep, Inflammatory Symptoms

Quick Fact: Relief for Deep, Inflammatory Symptoms and Chronic Resistance is relevant for easing symptoms, and may assist in supporting the patient through periods of heightened discomfort and contributing to minimizing the risk of permanent scarring.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Official Eligibility and Contraindications

Regulatory agencies strictly define the patient population eligible to use Isotina (Isotretinoin). Use is primarily indicated for patients 12 years of age and older with severe recalcitrant nodular acne that has proven unresponsive to conventional therapies, including systemic antibiotics.


Absolute Contraindications

Population Group Regulatory Status
Pregnancy Contraindicated (Category X)
Women of Childbearing Potential Contraindicated (Unless enrolled in a mandatory pregnancy prevention program and using dual contraception)
Breastfeeding/Nursing Contraindicated
Hepatic Insufficiency Contraindicated
Hypersensitivity Contraindicated (To isotretinoin, retinoids, or excipients like soya bean oil)
Concomitant Tetracyclines Contraindicated

Age and Condition Restrictions

Use is not established or not recommended in children under 12 years of age due to the risk of premature growth plate closure. Special caution is required for patients with pre-existing conditions, including severe renal insufficiency, diabetes, lipid metabolism disorders, or a history of psychiatric disorders [1.1, 2.6, 2.7].

What should I know about interactions with other medicines?

Interactions with other medicines and products

The following information describes officially documented drug and product interactions for isotretinoin, based on regulatory labeling.


Contraindicated and High-Risk Combinations

Certain combinations are absolutely restricted due to the potential for severe adverse effects:

  • Tetracycline Antibiotics: Co-administration is contraindicated because of the established risk of developing Pseudotumor Cerebri (Benign Intracranial Hypertension).
  • Vitamin A Supplements: Concurrent use is contraindicated due to the risk of additive toxic effects, leading to symptoms of Hypervitaminosis A.

Pharmacokinetic and Efficacy Interactions

Interacting Product Category Regulatory Statement
Hormonal Contraceptives (Minipills) Official documents note a potential risk of decreased efficacy for progesterone-only birth control preparations. Two reliable methods of contraception must be used concurrently.
CYP3A4 Substrates Isotretinoin and its metabolites are associated with a modest increase in CYP3A4 activity and may reduce the plasma concentrations of certain sensitive co-administered substrates.
Food / Lipids Standard formulations must be taken with food (specifically a high-fat meal) to ensure proper systemic absorption, as bioavailability is significantly enhanced by lipids.

Population-Specific Considerations

Individuals with hypertriglyceridemia or high alcohol consumption are at an increased risk for developing severe hypertriglyceridemia when taking this product, which is a key interaction-related monitoring point.

Mechanism of Action

Isotina (isotretinoin) is a synthetic retinoid that undergoes isomerization to all-trans-retinoic acid (ATRA), which then functions as an agonist for nuclear retinoic acid receptors (RARs), predominantly RAR-gamma. This receptor-ligand complex translocates to the nucleus and modulates gene transcription by binding to retinoic acid response elements (RAREs) in the DNA promoter region.

Downstream transcriptional regulation notably increases the expression of pro-apoptotic proteins, including Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL), Insulin-like Growth Factor-Binding Protein-3 (IGFBP-3), and Neutrophil Gelatinase-Associated Lipocalin (NGAL), in the sebaceous gland sebocytes. This increased expression of pro-apoptotic signals initiates the caspase cascade, inducing apoptosis (programmed cell death) specifically in the sebocytes. The system-level physiological consequence of sebocyte apoptosis is a marked and sustained reduction in sebaceous gland size and functional activity, leading to a substantial decrease in sebum production and altered skin surface lipid composition. Isotretinoin also modulates the proliferation and differentiation of epidermal keratinocytes, contributing to a normalization of follicular epithelial cell turnover.

Dosage and Administration Information

How to Use Isotina: Administration Guidelines

Isotina (Isotretinoin) is a systemic retinoid reserved for use in severe recalcitrant nodular acne. Its administration and dosing are calculated based on body weight to achieve a therapeutic cumulative dose over a defined treatment period.


Administration and Dosing Schedule

Parameter Instruction
Route of Administration Oral administration only, via soft gelatin capsules.
Standard Daily Dosing Typically ranges from 0.5 to 1 mg/kg/day, determined by the prescriber based on patient weight and disease severity. The maximum recommended dose is 2 mg/kg/day.
Frequency The total daily dose is required to be administered in two divided doses (BID).
Duration and Retreatment A treatment course typically lasts 15 to 20 weeks. A minimum of 8 weeks must pass after completing the first course before a second course may be considered.
Administration Conditions Capsules must be swallowed whole with a full glass of liquid; they must not be crushed, broken, or chewed. Instructions regarding administration with or without food vary by specific formulation.

Procedural Structure and Adjustments

Procedural Structure: The use of the medicine is defined by a calculated daily dosage, divided and taken twice daily over a finite course. The long-term efficacy is associated with achieving a target cumulative dose over the entire treatment duration.

Population Adjustments: Use is approved for patients 12 years of age and older. For those with severe chronic renal failure, recommendations advise a reduced starting dose, such as 10 mg daily, which can be slowly increased as tolerated. If a dose is missed, it should be skipped, and the patient must resume the regular schedule without doubling the next dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Isotina

1. Evidence for Use in Severe Recalcitrant Nodular Acne

Research into Isotina (Isotretinoin) has primarily focused on its use in managing severe nodular acne and cystic acne, particularly where the condition has not responded to previous standard treatments. The evidence base consists of various study types, including Randomized Controlled Trials (RCTs), meta-analyses that combine results from many trials, and long-term observational studies.

These studies were used in research exploring how symptoms change over time in the observed populations. Researchers primarily measured clinical outcomes related to physical discomfort, such as the change in the number of acne lesions and scores on standardized physician-administered global severity scales. Studies report patterns where the measured count of inflammatory lesions was observed to change during the treatment period.

2. Study Designs and Primary Clinical Measurements

The available research describes various study designs that help contextualize how symptoms are measured. Controlled clinical trials were used in research exploring short-term symptom changes. The primary goal of these research contexts was to examine clinical concepts studied in relation to inflammatory or irritative states. For example, studies monitored changes in sebaceous gland activity and recorded observations related to the skin's physical appearance over defined time intervals.

3. Long-Term Studies and Durability of Response

Studies have explored the long-term patterns of duration of lesion reduction after the treatment course is finished. Research describes that the patterns of lesion reduction observed during the treatment phase were tracked for an extended period in many individuals. The available data show patterns related to how the administered dose over the full course of treatment was studied in relation to the duration of sustained response. However, research highlights changes measured during the study period, but the long-term effects are not fully established for all populations.

4. Research Gaps and Areas of Scientific Uncertainty

While the evidence contributes to understanding symptom patterns, several research limitations frames are recognized in the scientific literature. Follow-up durations were limited in many of the initial controlled trials. Another gap relates to standardization: historical studies used varying diagnostic criteria to define who qualified as having "severe recalcitrant nodular acne." This heterogeneity is a factor studied by researchers when comparing findings across available research. Finally, research is ongoing regarding the full characterization of very rare or delayed outcomes. Study results reflect the specific conditions under which they were conducted and research provides context but not individual predictions.

Key Studies & References

  1. Acne recurrence after treatment with oral isotretinoin: 5-year follow-up
  2. High-Dose Isotretinoin Treatment and the Rate of Retrial, Relapse, and Adverse Effects in Patients With Acne Vulgaris
  3. Isotretinoin - StatPearls (Overview of FDA-approved indications and mechanisms)
  4. NICE Guideline NG198: Acne vulgaris: management (Last updated: 07 December 2023)
  5. REPORT OF THE COMMISSION ON HUMAN MEDICINES ISOTRETINOIN EXPERT WORKING GROUP (26 April 2023) - GOV.UK

Frequently Asked Questions (FAQ)

Common questions about Isotina (FAQ)

Q: How quickly does Isotina start to clear up skin problems?

A: According to official product information, the course of treatment is typically 15 to 20 weeks. Studies indicate that improvement in acne symptoms may continue for up to three months even after the complete treatment course is finished. Studies indicate that the full benefit may take several months to realize.


Q: How long is a typical treatment course with Isotina?

A: Regulatory documents state that a standard treatment course with this medicine is typically 15 to 20 weeks. The treatment length is determined by the prescriber based on factors established in clinical practice.


Q: Can Isotina be used for acne scars or just active acne?

A: The medicine is officially indicated for the treatment of severe recalcitrant nodular acne. Official product information does not list the treatment of acne scars as a primary indication.


Q: Why does Isotina cause dryness in so many users?

A: The mechanism of action for this medication involves profoundly inhibiting the function and size of the sebaceous glands. This leads to a substantial reduction in the production of sebum (natural skin oil), which is the cause of the very common side effects of skin and lip dryness.


Q: Are the side effects of Isotina permanent?

A: Most common side effects, such as dry skin and lips, typically resolve after the treatment is stopped. However, official safety information notes that certain rare side effects, such as decreased night vision, may persist in some individuals after discontinuation of the medicine.


Q: Does Isotina affect your mood or cause depression?

A: Official warnings state that the drug has been associated with severe psychiatric effects, including depression, mood changes, and suicidal ideation. Regulatory warnings emphasize the need to monitor for any changes in mood or behavior during treatment.


Q: Is it normal to have an initial 'purge' or worsening of acne after starting Isotina?

A: Official warnings mention that skin irritation and a temporary worsening of acne may occur during the first few weeks of therapy. If skin irritation becomes severe, regulatory information advises consulting a healthcare professional.


Q: Can you drink alcohol while taking Isotina?

A: Official prescribing information advises caution regarding alcohol consumption. Individuals who engage in high alcohol consumption are documented to be at increased risk for developing severe high blood triglyceride levels (hypertriglyceridemia) while taking the medicine.


Q: How long after stopping Isotina can I get pregnant safely?

A: Due to the risk of severe birth defects, official risk management programs require that effective contraception methods be used for at least one month following the final dose of the medicine.


Q: Does taking Isotina with food make it absorb better?

A: Yes, official regulatory documents state that the oral absorption of the medicine is significantly enhanced when it is administered with a high-fat meal. This enhances the bioavailability, which is necessary for proper systemic effect.


Q: Can Isotina cause hair thinning or hair loss?

A: Official safety data lists temporary hair thinning as a reported adverse reaction. This effect typically resolves once treatment is discontinued.


Q: Can Isotina cause vision problems or dry eyes?

A: The drug commonly causes dry eyes and conjunctivitis. Additionally, official information notes that a rare side effect is decreased night vision, which may be temporary or, in some individuals, persistent.


Q: Is it okay to wax or get laser treatments while taking Isotina?

A: Regulatory guidance advises that skin procedures such as wax depilation, dermabrasion, and laser skin resurfacing should be avoided. This is recommended both during treatment and for a period after stopping due to the increased risk of scarring.


Q: When is the best time of day to take the Isotina capsule?

A: Official administration guidelines require that the total daily dose is administered in two divided doses. While a specific morning or evening time is not mandated, the medicine is required to be taken with food for proper absorption.


Q: Are there specific symptoms that mean I should stop taking Isotina immediately?

A: Official warnings describe specific severe symptoms that warrant immediate consultation with a healthcare professional. These include, but are not limited to, severe headache, blurred vision, dizziness, severe stomach pain, or new or worsening symptoms of depression.


Q: Does Isotina make skin more sensitive in the long run?

A: The official label notes that during treatment, the skin is more prone to sunburn, dryness, and irritation. This increased sensitivity to external factors may continue for a period after the medicine is stopped.


Q: Does Isotina relate to Vitamin A?

A: Yes, the medicine's active ingredient, isotretinoin, is classified as a synthetic retinoid. This means it is a structural derivative of naturally occurring Vitamin A.


Q: Can Isotina worsen cholesterol levels?

A: Official safety information notes that increases in blood lipids are a documented side effect. This includes temporary increases in blood triglyceride and cholesterol levels, which require regular monitoring during treatment.


Q: Does Isotina affect the growth plates in adolescents?

A: Official pediatric safety information states that premature closure of the epiphyses, also known as growth plates, has been reported with the use of this medicine in adolescents.


Q: How is the dosage of Isotina determined for a person?

A: Regulatory information indicates that the dosage for an individual is calculated by the prescriber. This calculation is based on the patient's body weight and the severity of their acne condition.


Q: Does Isotina work for cystic acne?

A: The medicine is indicated for severe recalcitrant nodular acne. Nodular acne is a severe form of acne that includes large, deep, painful lesions often categorized as cystic acne.


Q: Is it normal for Isotina to make your scalp dry?

A: The medicine is associated with very common systemic side effects that include general dry skin (xerosis). Because this effect impacts the whole body system, it can certainly include dryness of the scalp.


Q: Will I need follow-up appointments after finishing my Isotina course?

A: Yes, follow-up is necessary. Regulatory risk management programs require women of childbearing potential to have a final negative pregnancy test one month after the last dose of treatment.


Q: What are the chances of acne coming back after stopping Isotina?

A: Official guidance states that acne may continue to improve even after a course of treatment is finished. For this reason, official guidance states that a minimum period of eight weeks must pass after the first course is completed before retreatment can be considered.


Q: Does Isotina affect your ability to drive or operate machinery?

A: Official warnings note that the medicine may cause rare side effects like decreased night vision, and may cause dizziness. Caution is advised regarding driving or operating machinery, particularly at night.


Q: Can someone with diabetes safely take Isotina?

A: Official guidelines indicate that patients with pre-existing conditions like diabetes require special caution. Special caution is advised, and frequent monitoring of blood sugar levels may be necessary.


Q: What are the regulations or programs associated with prescribing Isotina?

A: Due to the medicine's high risk of causing severe birth defects, regulatory bodies mandate a strict risk management program. In the U.S., this is the iPLEDGE program, which involves specific conditions for prescribing and dispensing.


Q: Do people who take Isotina need to use a strong sunscreen?

A: Regulatory guidance indicates that the medicine increases skin sensitivity to the sun. Therefore, using a high-protection factor sunscreen (SPF 30 or higher) is important, and direct, prolonged sun exposure is advised against.


Q: Does Isotina cause temporary or permanent changes to skin texture?

A: The mechanism of action involves profoundly altering the skin’s physiology, specifically reducing sebaceous gland size and activity. These systemic changes affect the skin texture both during and after the treatment period.


Q: Does Isotina cause joint pain or muscle aches?

A: Yes, official safety data lists both back pain and arthralgia (joint pain) as very common side effects. Muscle aches have also been reported with the use of the medicine.


Q: How long does it take for side effects like dry lips to go away after stopping Isotina?

A: The medicine is generally cleared from the body approximately one month after the last dose. Most common side effects, such as dry lips, typically begin to improve within one to two weeks after treatment is stopped.


Q: Why is Isotina sometimes called a systemic treatment?

A: It is classified as a systemic dermatological agent because it is taken orally, allowing it to be absorbed and distributed throughout the entire body system. This means it acts on internal body functions, rather than just on the surface of the skin.


Q: Can Isotina be taken long-term for mild acne?

A: No, official prescribing information restricts the indication to severe recalcitrant nodular acne. It is intended to be used for a finite treatment course, typically 15 to 20 weeks, and is not indicated for long-term use or for treating mild acne.


Q: Does Isotina affect the effectiveness of dental procedures or surgeries?

A: Official warnings note that the medicine can affect wound healing and may increase the risk of scarring. It is important to discuss potential procedural conflicts with a healthcare professional before scheduling any elective dermatologic or cosmetic procedures.


Q: Are the initial side effects the worst, or do they get worse over time?

A: Official information suggests that side effects such as skin irritation and sun sensitivity are often most noticeable during the first few weeks. However, official warnings advise that any severe or worsening symptom should be reported to a healthcare professional, as serious side effects can occur at any time.


Q: Is Isotina ever prescribed in lower doses for less severe conditions?

A: The official indication is strictly for severe recalcitrant nodular acne. Any use of the medicine for conditions less severe than this is considered outside of the regulatory product label.

How should Isotina be stored and disposed of?

How to Store and Dispose of Isotina?

Regulatory authorities define strict requirements for storing and disposing of isotretinoin capsules to maintain the drug's stability and ensure safety.

Storage Requirements

The medicine must be stored at Controlled Room Temperature, which is 20 C to 25 C (68 F to 77 F). The capsules must be protected from light and kept in the original container to preserve integrity. It is mandatory to keep the product out of the sight and reach of children at all times.

Disposal Instructions

Unused or expired isotretinoin must be disposed of according to local regulations. Official guidance specifies that the product must not be thrown away via wastewater or household waste and recommends utilizing established pharmaceutical take-back programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Isotina found in:

A-Z Index: